Marisa Wexler, MS, senior science writer —

People with multiple sclerosis (MS) who smoke tobacco or are not physically active are more likely to experience fatigue that interferes with their daily life, a new study indicates. The findings suggest that physical exercise and quitting smoking could help ease fatigue in people with MS. The study, “…

Two global Phase 3 clinical trials testing the investigational oral medication evobrutinib are recruiting participants with relapsing forms of multiple sclerosis (MS). The two identically-designed trials — EVOLUTION RMS 1 (NCT04338022) and EVOLUTION RMS 2 (…

People with multiple sclerosis (MS) and their nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta (ofatumumab) over other methods for injecting treatments, according to a survey. The survey was conducted by Novartis, which markets Kesimpta. Full findings from the survey will be presented at…

The Scottish Medicines Consortium (SMC) has approved Zeposia (ozanimod) for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Zeposia is sold as a tablet, to be taken by mouth once daily. The SMC has recommended that Zeposia be prescribed for people with RRMS who experience relapses or have evidence of…

A novel medication targeting the protein folate receptor-beta (FR-beta) decreased inflammation and brain damage in a rat model of multiple sclerosis (MS). The findings were published in the Journal of Neuroinflammation, in the study “Efficacy and tolerability of folate-aminopterin therapy in a rat focal model of…

The U.S. Food and Drug Administration (FDA) has approved an intramuscular injection formulation of Plegridy (peginterferon beta-1a) to treat people with relapsing forms of multiple sclerosis (MS). This formulation, for injection directly into muscle, is what is typically used to deliver the flu shot. According to Biogen, Plegridy’s…

A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease. A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows…

Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patient‐perceived physical and functional abilities with multiple sclerosis (MS), as well as their utilization of select healthcare services, a real-world study suggests. Its researchers, however, stress that more work is needed before NfL levels…

Oleic acid, a type of fatty acid, is important for the function of immune cells that are dysregulated in multiple sclerosis (MS), an early study shows. A diet rich in oleic acid may potentially be beneficial for these patients, although researchers emphasized the need for more studies. The study,…

Clene Nanomedicine has been notified it will be given a U.S. patent, as requested, covering an invention using the company’s already patented gold nanocrystals for the treatment of multiple sclerosis (MS). A Notice of Allowance was received by the company. These notices are issued by the U.S. Patent…

Helius Medical Technologies has submitted its response to the U.S. Food and Drug Administration (FDA)’s request for more information about the company’s application for de novo classification and clearance of its portable neuromodulation stimulator (PoNS) device to help treat walking difficulties in people…

To fully understand autoimmune diseases like multiple sclerosis (MS), it is necessary to study not just the immune system, but also the tissue that the immune system is attacking, a study suggests. “We must move away from the present ‘immune-centric-only’ view of autoimmune diseases,” Decio Eizirik, MD, PhD, study…

The Multiple Sclerosis Association of America (MSAA) is hosting a webinar in which experts will discuss the COVID-19 pandemic and its impact on multiple sclerosis (MS). The webinar, “What You Need to Know About COVID-19 and MS: Program 8,” will take place at 8 p.m.

A new research project will seek to better understand the biological processes that drive memory problems in people with multiple sclerosis (MS), as a better understanding of these processes may open new avenues for intervention. The four-year study is titled “Neuroimaging of Hippocampally Mediated Memory Dysfunction in…

People with multiple sclerosis (MS) may have cognitive defects that cannot be detected using conventional paper-and-pen tests but that can be assessed with computer-based tests, a new study shows. The findings also indicate that people with MS may be more susceptible to cognitive impairment when the brain has to address increased…

An upcoming Phase 2 clinical trial, called ChariotMS, will test whether Mavenclad (cladribine) can slow a worsening of hand and arm function in people with progressive multiple sclerosis (MS) and very limited walking abilities. Patients reliant on wheelchairs or aids to walk even short distances generally have…

A software platform, called CogniSoft, allows for automated assessments of cognitive health in people with multiple sclerosis (MS). The platform was described in the study “CogniSoft: A Platform for the Automation of Cognitive Assessment and Rehabilitation of Multiple Sclerosis,” published in the journal Computers. Cognitive impairment…

The U.K.’s MS Trust has been awarded £50,000 (about $65,800) from the Coronavirus Community Support Fund — distributed by The National Lottery Community Fund — to further its “Supporting the MS community during Covid-19” project. Expected to run for six months, the project aims…

The levels of the protein neurofilament light chain (NfL) in the blood when a person experiences a first demyelinating event associated with multiple sclerosis (MS) can predict brain atrophy up to a decade later, a new study shows. Titled “Association of Serum Neurofilament Light Levels…

Eligible people with relapsing-remitting multiple sclerosis (RRMS) now have access to Mavenclad (cladribine) through seven provincial public drug plans in Canada, including the Régie de l’assurance maladie du Québec (RAMQ) and the Ontario Drug Benefit Exceptional Access Program. The oral treatment now is available through public drug programs…

A newly identified population of immune cells contributes to inflammation in multiple sclerosis (MS), a new study suggests. The study, “A distinct GM-CSF+ T helper cell subset requires T-bet to adopt a TH1 phenotype and promote neuroinflammation,” was published in Science Immunology. MS is an…

A genetic variant may make depression more likely in certain people with multiple sclerosis (MS) than others, a genome-wide study in patients indicates. The study, “Depression in multiple sclerosis patients associated with risk variant near NEGR1,” was published in Multiple Sclerosis and Related Disorders. Depression is characterized by…

Mayzent (siponimod) has become the first oral medication to be approved for people with active secondary progressive multiple sclerosis (SPMS) in England and Wales. Following this decision by England’s National Institute for Health and Care Excellence (NICE) — which reversed its opinion announced in June — the…

Health Canada has approved Zeposia (ozanimod), an oral daily treatment for people with relapsing-remitting multiple sclerosis (RRMS) in the country. Approval does not assure that Zeposia will be available to Canadian patients at no or low cost, as publicly funded prescription plans are largely administered by each…

Connectivity between parts of the brain related to vision and attention is altered in people with relapsing-remitting multiple sclerosis (RRMS), both during rest and while actively engaged in a task, a new study indicates. The study, “Altered brain network function during attention-modulated visual processing in multiple…

Gilenya (fingolimod) and Tecfidera (dimethyl fumarate) are similarly effective at lowering the frequency of relapses and delaying disability progression in people with relapsing-remitting multiple sclerosis (RRMS), a real-world study from Switzerland reported. These efficacy measures were also consistent whether patients were new to a disease-modifying therapy (DMT)…

The U.S. Food and Drug Administration (FDA) has accepted an investigational new drug application (IND) for ANK-700, a treatment candidate for multiple sclerosis (MS) that is being developed by the Swiss company Anokion. With this approval, Anokion can enter clinical testing and is planning to…

People in Texas with multiple sclerosis (MS) and other medical conditions now have access to cannabis-infused lozenges, Surterra Texas announced. Under a Texas Compassionate Use Program, cannabis-containing therapies may be prescribed to help treat various neurological and other disorders, including terminal cancer, spasticity,…

More than 2.8 million people worldwide are now estimated to be living with multiple sclerosis (MS), including about 1 million in the United States, an update to the Atlas of MS reports. An increase since its previous update, this number translates to someone, somewhere in the world, being newly diagnosed with…

Novartis is not planning to open a clinical trial of Kesimpta (ofatumumab) as a potential treatment for primary progressive multiple sclerosis (PPMS) anytime soon, a company executive said. But it is well aware of the “unmet need” for therapy options among this patient group, and is exploring avenues. “We do…